Conclusion:
This report aims to highlight the clinicians with the possibility of a dose-independent and fatal aplastic anemia secondary to Temozolomide. When seeing patients on Temozolomide with pancytopenia, aplastic anemia secondary to the drug should be considered early in the differentials to avoid permanent hematological suppression.